Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.

Objective: Cushing's disease, hypercortisolism due to a pituitary ACTH-secreting tumour, is a highly morbid illness as yet without effective medical therapy. Recent studies have demonstrated that peroxisome proliferator-activated receptor gamma (PPARgamma) agonists effectively suppress ACTH secretion in a murine tumoral corticotroph cell line, but the few studies conducted so far in patients with ACTH-secreting pituitary adenomas have yielded variable results.

Design: Ten patients with Cushing's disease were treated with 4-16 mg rosiglitazone p.